Therapeutics / Drugs / Drug / Biosciences / Applied / Biotech / BioTech / Boston / Boston blog main / Boston top stories / Detroit blog main / National blog main / San Diego blog main / San Diego top stories / clinical trials / Federal government shutdown 2019 / Flagship Pioneering / Frazier Healthcare Partners / Government Shutdown / Hepatic Encephalopathy / hyperammonemia / investing / IPO / Kaleido Biosciences / Life Sciences / Metabolic Diseases / Microbiome / nonalcoholic steatohepatitis / Novo Holdings / Oceta Therapeutics / SEC / startups / thiazolidinedioine / urea cycle disorder

Kaleido Bio and Cirius Join an IPO Queue Stalled by Federal Shutdown

Posted on: Jan 12, 2019   |   Posted by: Biotech Mag Top

Kaleido Bio and Cirius Join an IPO Queue Stalled by Federal Shutdown

The partial government shutdown may have diminished staffing at the SEC but it hasn't dimmed the hopes of biotech firms hoping to go public. On Friday, Kaleido Biosciences and...

Continue reading ...